European public procurement and grants data from official registers · Data as of 18 November 2026; updated daily.

Tenders

Oncology drug tenders in Slovakia

Oncology drug tenders in Slovakia: 55 listed on GranTender since 2024; none is open now. The median awarded contract value is about €69,000 (200 contracts with a stated value). Buyers with the most tenders: Všeobecná zdravotná poisťovňa, a. s. (15), Fakultná nemocnica s poliklinikou Žilina (13) and Národný ústav reumatických chorôb (5); suppliers with the most contract awards: MED - ART, spol. s r.o. (95), UNIPHARMA - 1. slovenská lekárnická akciová spoločnosť (49) and BAX PHARMA, s.r.o. (20). Sources: Centrálny register zmlúv and TED. In 2025 the median contract value was €150,000; 44% of contracts drew a single bid (2.1 bids on average). Data as of 18 November 2026; updated daily.

Tenders
55
Open tenders
0
Awards
218
Awarded value awarded
€83,733,134
Awarded value framework ceiling
€10,165,516
Median contract value awarded
≈ €69,000
Median contract value framework ceiling
≈ €330,000
Average bids per contract
2.2
Tenders in 2025
25 +47% on 2024

Median: contracts with a stated value, rounded. Average bids: contracts where the number of bids is published.

Value kinds: awarded — the value in the award decision; contract — the value of the signed or amended contract; paid — the amount actually paid; framework ceiling — the maximum of a framework agreement, given with every winner, not money spent. Different kinds are never added together.

Open tenders

No records yet.

Latest tenders

TenderBuyerEstimated valueStatusPublished
Antineoplastické a imunomodulačné činidláFakultná nemocnica s poliklinikou Žilina€947,649Closed9 October 2026
LIEKY S ÚČINNOU LÁTKOU ANIFROLUMAB 2026Národný ústav reumatických chorôb—Closed5 October 2026
PRK - LIEKY S ÚČINNOU LÁTKOU BELIMUMAB 2026Národný ústav reumatických chorôb—Awarded28 August 2026
Antineoplastické a imunomodulačné činidláFakultná nemocnica s poliklinikou Žilina€251,287Closed28 August 2026
Lieky ATC skupiny L01CD01, účinná látka Paklitaxel, parent nanočastice viazané na albumín 100 mgVšeobecná zdravotná poisťovňa, a. s.€4,250,060Closed13 August 2026
Antineoplastické a imunomodulačné činidláFakultná nemocnica s poliklinikou Žilina€3,168,914Closed2 July 2026
Antineoplastické a imunomodulačné činidlá ( bežné )Fakultná nemocnica s poliklinikou Žilina€150,026Closed15 June 2026
Lieky ATC skupiny L04AB02, Infliximab parent. 100 mgVšeobecná zdravotná poisťovňa, a. s.€2,667,150Awarded28 May 2026
LIEKY PRE BIOLOGICKÚ LIEČBU 2026Národný ústav reumatických chorôb—Awarded21 April 2026
Antineoplastické činidlá pre nemocničnú lekáreňŠpecializovaná nemocnica sv. Svorada Zobor, n.o.€255,613Awarded8 April 2026
Lieky ATC skupiny L03AB07Všeobecná zdravotná poisťovňa, a. s.€1,449,576Awarded18 March 2026
Lieky ATC skupiny L01BC07Všeobecná zdravotná poisťovňa, a. s.€266,050Awarded18 March 2026
Imunosupresívne činidláÚstredná Vojenská Nemocnica SNP Ružomberok - Fakultná Nemocnica€734,229Awarded22 December 2025
Lieky ATC skupiny L01FA01Všeobecná zdravotná poisťovňa, a. s.€6,015,810Awarded19 November 2025
Lieky RVO/3652/2025 v rozsahu Antipsychotiká, Immunopreparáta, Antireumatiká, Chemoterapeutiká,Vazopresoriká, Spasmolytiká, Antidotum, Sympatomimetiká, Vitamíny, Varia, Antimykotiká na systémové použitieFakultná nemocnica s poliklinikou F. D. Roosevelta Banská Bystrica€4,014,759Awarded29 October 2025
Lieky ATC skupiny L01FG01Všeobecná zdravotná poisťovňa, a. s.€15,084,140Awarded9 July 2025
Antineoplastické a imunomodulačné činidláFakultná nemocnica s poliklinikou Žilina€603,673Awarded1 July 2025
Imunosupresívne činidláUniverzitná nemocnica Martin€9,814,956Awarded17 June 2025
PembrolizumabFakultná nemocnica Trnava—Closed12 June 2025
Liek s účinnou látkou blinatumomabDetská fakultná nemocnica s poliklinikou Banská Bystrica€165,611Awarded6 June 2025

Competition and prices

In 2025, half of the contracts were worth between €21,000 and €610,000, with a median of €150,000 (74 contracts with a stated awarded value). Contracts drew 2.1 bids on average (median 2) and 44% drew a single bid — based on 79 contracts with a known number of bids. Compared with 2024, in 2025 the median value fell 12% and the share of single-bid contracts rose from 35% to 44%. The usual procedures: open procedure (96%), negotiation without a call for competition (2%), restricted procedure (2%) — of 55 tenders with a stated procedure.

The most contracts went to MED - ART, spol. s r.o. (95), UNIPHARMA - 1. slovenská lekárnická akciová spoločnosť (49) and BAX PHARMA, s.r.o. (20) — together 75% of all contracts.

YearContractsMedian valueMiddle half of valuesBids on averageSingle bid
202431€170,000€39,000 – €390,0002.035% (31)
202579€150,000€21,000 – €610,0002.144% (79)
2026 (so far)81€46,000€12,000 – €260,0002.328% (80)
All years218€69,000€15,000 – €340,0002.233% (217)

Values: contracts with a stated value in EUR, each value kind on its own (awarded or contract value), approximate (±3 %). Bids: contracts of procedures with competition whose number of bids the source publishes (1–100 bids); the sources publish it for some contracts only (TED ≈ 3 in 4, Spain all, Poland about half, Italy few), so each figure states its base and is shown from 20 contracts. A contract counts in the year of its award (else of its tender). Figures as of 13 November 2026, recomputed every week.

Where you have a chance

Since 1 November 2024, 36% of the 159 contracts with a known number of bids had a single bid; the median was 2 bids. The number of bids is known for 159 of the 159 contracts from procedures with competition.

Buyers who often get few offers

The buyers below usually received one or two offers per contract — an offer from you would stand out.

In the last 12 months, 0 companies won their first contract in our records here — 0% of the 86 contracts (our records start on 1 January 2024).

Contracts awarded since 1 November 2024 (the last 24 months). Bids as the source publishes them, 1 to 100 per contract, in procedures with competition only (a direct award has one offer by design). As of 13 November 2026.

Main CPV divisions

CPV codes of this topic

  • 33652000 Antineoplastic and immunomodulating agents

A tender belongs here when its main CPV code starts with one of these codes; a tender without a usable CPV code (or with a general one) is matched by words of its title. A tender may belong to up to three topics.

Oncology and immunomodulating drugs in neighbouring countries

Today, 65 tenders in the same niche are open in neighbouring countries.

Public tenders in the EU and the EEA are open to companies from every EU and EEA country on the same terms as local ones, and to companies from countries with a procurement agreement with the EU (such as Switzerland, the United Kingdom and Ukraine) for the contracts it covers. In countries outside the EU and the EEA, the notice says who may bid. Open means the deadline has not passed (today's date). Neighbours: countries with a land border, a fixed link or a short sea crossing.

Expected soon4

ExpectedBuyerWhatWhy we expect itConfidence
Dec 2026 – May 2027
contract ends
Špecializovaná nemocnica sv. Svorada Zobor, n.o.Oncology and immunomodulating drugs
Antineoplastické činidlá pre nemocničnú lekáreň
Typical value: ≈ €71,000
The current contract with MED - ART, spol. s r.o. ends on 1 June 2027 (from its stated duration); no new tender has been published yet.
Earlier tenders: 04/2026
high
Dec 2026 – Jan 2027
every year
Ústredná Vojenská Nemocnica SNP Ružomberok - Fakultná NemocnicaOncology and immunomodulating drugs
Imunosupresívne činidlá
Typical value: ≈ €700,000
The buyer has published oncology drug tenders every year in December since 2024. The current contract with Roche Slovensko, s.r.o. ends on 21 May 2027 (from its stated duration); no new tender has been published yet.
Earlier tenders: 12/2025, 12/2024, 01/2024
high
Dec 2026 – May 2027
contract ends
Národný Endokrinologický a Diabetologický Ústav N. O.Oncology and immunomodulating drugs
Lieky a zdravotnícke pomôcky
Typical value: ≈ €260,000
The current contract with LK1 s. r. o. ends on 10 June 2027 (from its stated duration); no new tender has been published yet.
Earlier tenders: 04/2025
medium
Jan – Jun 2027
contract ends
Detská fakultná nemocnica s poliklinikou Banská BystricaOncology and immunomodulating drugs
Dinutuximab 4,5 mg/1 ml, koncentrát na infúzny roztok
Typical value: ≈ €900,000
The current contract with MED - ART, spol. s r.o. ends on 11 July 2027 (from its stated duration); no new tender has been published yet. The current contract with MED - ART, spol. s r.o. ends on 20 August 2027 (from its stated duration); no new tender has been published yet.
Earlier tenders: 04/2025, 06/2025
high

Forecast from public data, not an announcement. Methodology.

Oncology and immunomodulating drugs by city

Oncology and immunomodulating drugs in other countries

Oncology and immunomodulating drugs across Europe

Topics in Health, medical equipment and medicines

Questions and answers

Which oncology drug tenders in Slovakia are open now?
None is open at the moment; GranTender lists 55 in total.
Where can I find oncology drug tenders in Slovakia?
GranTender lists them in one place, from Centrálny register zmlúv and TED, with their buyers, winners and contract values; 0 are open now. Search in one country at a time (the first 5 results) is free; search across all countries at once, full result lists, saved keywords with an e-mail once a week and exports come with a plan.
Who wins the most oncology drug tenders in Slovakia?
By number of contracts won: MED - ART, spol. s r.o. (95), UNIPHARMA - 1. slovenská lekárnická akciová spoločnosť (49), BAX PHARMA, s.r.o. (20).
Which buyers publish the most oncology drug tenders in Slovakia?
By number of tenders: Všeobecná zdravotná poisťovňa, a. s. (15), Fakultná nemocnica s poliklinikou Žilina (13), Národný ústav reumatických chorôb (5).
Which CPV codes belong to “Oncology and immunomodulating drugs”?
33652000 Antineoplastic and immunomodulating agents; plus tenders without a usable CPV code whose title names the topic.
How many bids do oncology drug tenders in Slovakia receive on average?
In 2025, contracts drew 2.1 bids on average (median 2) and 44% drew a single bid — based on 79 contracts with a known number of bids.
How much are contracts for oncology drug tenders in Slovakia worth?
In 2025, half of the contracts were worth between €21,000 and €610,000, with a median of €150,000 (74 contracts with a stated awarded value). Compared with 2024, in 2025 the median value fell 12% and the share of single-bid contracts rose from 35% to 44%.
Which procedures are used for oncology drug tenders in Slovakia?
The usual procedures: open procedure (96%), negotiation without a call for competition (2%), restricted procedure (2%) — of 55 tenders with a stated procedure.
Which buyers get few offers in oncology drug tenders in Slovakia?
Since 1 November 2024, these buyers usually received one or two offers per contract: Univerzitná nemocnica Martin (median 2 bids over 62 contracts), Ústredná Vojenská Nemocnica SNP Ružomberok - Fakultná Nemocnica (median 2 bids over 18 contracts) and Národný Endokrinologický a Diabetologický Ústav N. O. (median 1 bid over 13 contracts). Since 1 November 2024, 36% of the 159 contracts with a known number of bids had a single bid; the median was 2 bids.

CPV 2008 (Regulation (EC) No 213/2008), © European Union, Publications Office — via the eForms SDK, CC BY 4.0.